Morgan Stanley Maintains Equal-Weight on Genmab, Maintains $31 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Vikram Purohit has maintained an Equal-Weight rating on Genmab (NASDAQ:GMAB) with a price target of $31.
September 11, 2024 | 3:36 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley has reiterated its Equal-Weight rating for Genmab with a $31 price target, indicating a neutral stance on the stock's short-term performance.
The reiteration of an Equal-Weight rating and a maintained price target of $31 suggests that Morgan Stanley sees no immediate catalysts for significant price movement in Genmab's stock. This neutral stance implies that the stock is expected to perform in line with the market.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100